Bibliography
- * of interest
- ** of considerable interest
- Thomas D. Global control of hepatitis C: where challenge meets opportunity. Nat Med. 2013;19:850–858.
- Gower E, Estes C, Blach S, et al. Global epidemiology and genotype distribution of the hepatitis C virus infection. J Hepatol. 2014;61(suppl):45–57.
- CDC. Hepatitis C information. 2015 [cited 2015 Sep]. Available at: www.cc.gov/hepatitis/HCV
- EASL. Clinical Practice Guidelines: management of hepatitis C virus infection. J Hepatol. 2014;60:392–420.
- Berenguer M. Natural history of recurrent hepatitis C. Liver Transpl. 2002;8(suppl 10):S14–8.
- EASL. Recommendations on treatment of hepatitis C 2015. J Hepatol. 2015;63:199–236.
- Vispo E, Barreiro P, Soriano V. Pharmacokinetics of new oral hepatitis C antiviral drugs. Expert Opin Drug Metab Toxicol. 2013;9:5–16.
- Gentile I, Buonomo A, Zappulo E, et al. Interferon-free therapies for chronic hepatitis C: toward a hepatitis C virus free world? Expert Rev Anti Infect Ther. 2014;12:763–773.
- Pawlotsky JM. New hepatitis C therapies: the toolbox, strategies, and challenges. Gastroenterology. 2014;146:1176–1192.
- Conjeevaram H. Continued progress against hepatitis C infection. JAMA. 2015;313:1716–1717.
- Muir A, Naggie S. HCV treatment: is it possible to cure all HCV patients? Clin Gastroenterol Hepatol. 2015;13:2166–2172.
- Chtioui H, Buclin T, Moradpour D. New hepatitis C treatments: pharmacological considerations and potential for drug interactions. Rev Med Suisse. 2014;10:1600–1604.
This manuscript is a brief summary of major drug interactions of new oral hepatitis C drugs. It includes very helpful tables.
- Soriano V, Labarga P, Barreiro P, et al. Drug interactions with new hepatitis C oral drugs. Expert Opin Drug Metab Toxicol. 2015;11:333–341.
- Burger D, Back D, Buggisch P, et al. Clinical management of drug-drug interactions in HCV therapy: challenges and solutions. J Hepatol. 2013;58:792–800.
This is a pivotal review on major drug-drug interactions of new oral HCV drugs, written by pharmacologists with large expertise in antivirals and robust clinical knowledge.
- Kiser J, Burton J, Everson G. Drug-drug interactions during antiviral therapy for chronic hepatitis C. Nat Rev Gastroenterol Hepatol. 2013;10:596–606.
This review summarizes the most relevant information on mechanisms of drug interactions expected and/or clinically observed using new oral hepatitis C drugs.
- Ahmad T, Yin P, Saffitz J, et al. Cardiac dysfunction associated with a nucleotide polymerase inhibitor for treatment of hepatitis C. Hepatology. 2015;62:409–416.
- Soriano V, Esposito I. Caution with new oral hepatitis C drugs. AIDS Rev. 2015;17:121–122.
- Karageorgopoulos D, El-Sherif O, Bhagani S, et al. Drug interactions between antiretrovirals and new or emerging direct-acting antivirals in HIV/HCV coinfection. Curr Opin Infect Dis. 2014;27:36–45.
This is a comprehensive and updated review on the major drug–drug interactions between antivirals in HIV-HCV coinfected patients.
- Esposito I, Labarga P, Barreiro P, et al. Dual antiviral therapy for HIV and HCV – drug interactions and side effects. Expert Opin Drug Saf. 2015;14:1421–1434.
- Tischer S, Fontana R. Drug-drug interactions with oral anti-HCV agents and idiosyncratic hepatotoxicity in the liver transplant setting. J Hepatol. 2014;60:872–884.
- Toussaint-Miller K, Andres J. Treatment considerations for unique patients populations with HCV genotype 1 infection. Ann Pharmacother. 2015;49:1015–1030.
- Gane E, Roberts S, Stedman C, et al. Oral combination therapy with a nucleoside polymerase inhibitor (RG7128) and danoprevir for chronic hepatitis C genotype 1 infection (INFORM-1): a randomised, double-blind, placebo-controlled, dose-escalation trial. Lancet. 2010;376:1467–1475.
- Wiktor S. Deciding who should be treated for hepatitis C infection in a rapidly changing therapeutic landscape. Hepatology. 2015;62:13–15.
- Jensen D, O’Leary J, Pockros P, et al. Safety and efficacy of sofosbuvir-containing regimens for hepatitis C: real-world experience in a diverse, longitudinal observational cohort. AASLD 2014, Boston, MA. November 7-11 2014 [abstract 45]. Hepatology. 2014;60(suppl):219A.
- Dieterich D, Bacon B, Flamm S, et al. Evaluation of sofosbuvir and simeprevir-based regimens in the TRIO network: academic and community treatment of a real world, heterogeneous population. AASLD 2014, Boston, MA. November 7-11 2014 [abstract 46]. Hepatology. 2014;60(suppl):220A.
- Ferenci P, Bernstein D, Lalezari J, et al. ABT-450/r-ombitasvir and dasabuvir with or without ribavirin for HCV. N Engl J Med. 2014;370:1983–1992.
- Bourliere M, Sulkowski M, Omata M, et al. An integrated safety and efficacy analysis of >500 patients with compensated cirrhosis treated with ledipasvir/sofosbuvir with or without ribavirin. AASLD 2014, Boston, MA [abstract 82]. Hepatology. 2014;60(suppl):239A.
- Hézode C, Asselah T, Reddy K, et al. Ombitasvir plus paritaprevir plus ritonavir with or without ribavirin in treatment-naive and treatment-experienced patients with genotype 4 chronic hepatitis C virus infection (PEARL-I): a randomised, open-label trial. Lancet. 2015;385:2502–2509.
- Lawitz E, Gane E, Pearlman B, et al. Efficacy and safety of 12 weeks versus 18 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin for hepatitis C virus genotype 1 infection in previously untreated patients with cirrhosis and patients with previous null response with or without cirrhosis (C-WORTHY): a randomised, open-label phase 2 trial. Lancet. 2015;385:1075–1086.
- Poordad F, Sievert W, Mollison L, et al. Fixed-dose combination therapy with daclatasvir, asunaprevir and beclabuvir for non-cirrhotic patients with HCV genotype 1 infection. JAMA. 2015;313:1728–1735.
- Muir A, Poordad F, Lalezari J, et al. Daclatasvir in combination with asunaprevir and beclabusvir for hepatitis C virus genotype 1 infection with compensated cirrhosis. JAMA. 2015;313:1736–1744.
- Hassanein T, Sims K, Bennett M, et al. A randomized trial of daclatasvir in combination with asunaprevir and beclabusvir in patients with chronic hepatitis C virus genotype 4 infection. J Hepatol. 2015;62:1204–1206.
- Treviño A, De Mendoza C, Parra P, et al. Natural polymorphisms associated with resistance to new antivirals against HCV in newly diagnosed HIV-HCV-coinfected patients. Antivir Ther. 2011;16:413–416.
- Poveda E, Wyles D, Mena A, et al. Update on hepatitis C virus resistance to direct-acting antiviral agents. Antiviral Res. 2014;108:181–191.
- Nguyen L, Gray E, Dean J, et al Baseline prevalence and emergence of protease inhibitor resistance mutations following treatment in chronic HCV genotype 1-infected individuals. Antivir Ther. 2015 Apr 29. DOI:10.3851/IMP2964. [Epub ahead of print].
- Barreiro P, Fernandez-Montero JV, De Mendoza C, et al. Towards hepatitis C eradication from the HIV-infected population. Antiviral Res. 2014;105:1–7.
- Jiménez-Nácher I, Alvarez E, Morello J, et al. Approaches for understanding and predicting drug interactions in HIV-infected patients. Expert Opin Drug Metab Toxicol. 2011;7:457–477.
- You D, Pockros P. Simeprevir for the treatment of chronic hepatitis C. Expert Opin Pharmacother. 2013;14:2581–2589.
- Gentile I, Borgia F, Buonomo A, et al. ABT-450: a novel protease inhibitor for the treatment of hepatitis C virus infection. Curr Med Chem. 2014;21:3261–3270.
- Sofia M. Beyond sofosbuvir: what opportunity exists for a better nucleoside/nucleotide to treat hepatitis C? Antivir Res. 2014;107:119–124.
- Soriano V, Vispo E, De Mendoza C, et al. Hepatitis C therapy with HCV NS5B polymerase inhibitors. Expert Opin Pharmacother. 2013;14:1161–1170.
- Labarga P, Barreiro P, Martin-Carbonero L, et al. Kidney tubular abnormalities in the absence of impaired glomerular function in HIV patients treated with tenofovir. Aids. 2009;23:689–696.
This is a pivotal study that establishes the rate, timing and tubular nature of renal damage in patients exposed to tenofovir.
- Rockstroh J, Puoti M, Rodriguez-Torres M, et al. Sofosbuvir and ribavirin therapy for the treatment of HIV/HCV coinfected patients with HCV GT1-4 infection: the PHOTON-1 and −2 trials. AASLD 2014, Boston, MA [abstract 195]. Hepatology. 2014;60(suppl):295A.
- Osinusi A, Townsend K, Kohli A, et al. Virologic response following combined ledipasvir and sofosbuvir administration in patients with HCV genotype 1 and HIV coinfection. JAMA. 2015;313:1232–1239.
- Gentile I, Buonomo A, Borgia F, et al. Ledipasvir: a novel synthetic antiviral for the treatment of HCV infection. Expert Opin Investig Drugs. 2014;23:561–571.
- Aghemo A, De Francesco R. Daclatasvir: a team player rather than a prima donna in the treatment of hepatitis C. Gut. 2015;64:860–862.
- Wyles D, Ruane P, Sulkowski M, et al. Daclatasvir plus sofosbuvir for HCV in patients coinfected with HIV-1. N Engl J Med. 2015;373:714–725.
- Naggie S, Cooper C, Saag M, et al. Ledipasvir and sofosbuvir for HCV in patients coinfected with HIV-1. N Engl J Med. 2015;373:705–713.
- Sulkowski M, Eron J, Wyles D, et al. Ombitasvir, paritaprevir co-dosed with ritonavir, dasabuvir, and ribavirin for hepatitis C in patients co-infected with HIV-1: a randomized trial. JAMA. 2015;313:1223–1231.
- Piroth L, Paniez H, Taburet A, et al. High cure rate with 24 weeks of daclatasvir-based quadruple therapy in treatment-experienced, null-responder patients with HIV/HCV genotypes 1-4 coinfection: the ANRS HC30 QUADRIH study. Clin Infect Dis. 2015;61:817–825.
- Sulkowski M, Hezode C, Gerstoft J, et al. Efficacy and safety of 8 weeks versus 12 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin in patients with hepatitis C virus genotype 1 mono-infection and HIV/hepatitis C virus co-infection (C-WORTHY): a randomised, open-label phase 2 trial. Lancet. 2015;385:1087–1097.
- Stock P, Terrault N. HIV and liver transplantation: Hepatitis C is the last hurdle. Hepatology. 2015;61:1747–1754.
- Kwo P, Badshah M. New hepatitis C virus therapies: drug classes and metabolism, drug interactions relevant in the transplant settings, drug options in decompensated cirrhosis, and drug options in end-stage liver disease. Curr Opin Organ Transplant. 2015;20:235–241.
- Pellicelli A, Montalbano M, Lionetti R, et al. Sofosbuvir plus daclatasvir for post-transplant recurrent hepatitis C: potent antiviral activity but no clinical benefit if treatment is given late. Dig Liver Dis. 2014;46:923–927.
- Kwo P, Mantry P, Coakley E, et al. An interferon-free antiviral regimen for HCV after liver transplantation. N Engl J Med. 2014;371:2375–2382.
- Menon R, Badri P, Wang T, et al. Drug-drug interaction profile of the all-oral anti-hepatitis C virus regimen of paritaprevir/ritonavir, ombitasvir, and dasabuvir. J Hepatol. 2015;63:20–29.
- Stine J, Intagliata N, Shah N, et al. Hepatic decompensation likely attributable to simeprevir in patients with advanced cirrhosis. Dig Dis Sci. 2015;60:1031–1035.
- Soriano V, Barreiro P, De Mendoza C, et al. Hepatic decompensation with sofosbuvir plus simeprevir in a patient with Child-Pugh B compensated cirrhosis. Antivir Ther. 2015 Jun 4. DOI:10.3851/IMP2969. [Epub ahead of print].
- Charlton M, Everson G, Flamm S, et al. Ledipasvir and sofosbuvir plus ribavirin for treatment of HCV infection in patients with advanced liver disease. Gastroenterology. 2015;149:649–659.
- Poole R. Daclatasvir + Asunaprevir: first global approval. Drugs. 2014;74:1559–1571.
- Dyson J, Hutchinson J, Harrison L, et al Liver toxicity associated with sofosbuvir, an NS5A inhibitor and ribavirin use. J Hepatol. 2015 Aug 29. pii: S0168-8278(15)00589-9. DOI:10.1016/j.jhep.2015.07.041. [Epub ahead of print].
- Asselah T, Bruno S, Craxi A. HCV cirrhosis at the edge of decompensation: will paritaprevir with ritonavir, ombitasvir, dasabuvir and ribavirin solve the need for treatment? J Hepatol. 2014;61:1430–1433.
- Ferenci P, Kozbial K, Mandorfer M, et al. HCV targeting of patients with cirrhosis. J Hepatol. 2015;63:1015–1022.
- Saxena V, Nyberg L, Pauly M, et al. Safety and Efficacy of simeprevir/sofosbuvir in hepatitis C infected patients with compensated and decompensated cirrhosis. Hepatology. 2015;62:715–725.
- Jacobson I, Poordad F, Firpi-Morell R, et al. Efficacy and safety of grazoprevir and elbasvir in hepatitis C genotype 1-infected patients with Child-Pugh B cirrhosis (C-SALT part A). EASL, Vienna, Austria [abstract O008]. J Hepatol. 2015;62(suppl):193–194.
- Poordad F, Schiff E, Vierling J, et al. Daclatasvir, sofosbuvir and ribavirin combination for HCV patients with advanced cirrhosis or postransplant recurrence: phase 3 ALLY-1 study. EASL, Vienna, Austria [abstract L08]. J Hepatol. 2015;62(suppl):261.
- Gentile I, Buonomo A, Borgia G. Dasabuvir: A non-nucleoside inhibitor of NS5B for the treatment of hepatitis C virus infection. Rev Recent Clin Trials. 2014;9:115–123.
- Khatri A, Dutta S, Marbury T, et al. The pharmacokinetics and safety of the DAA ABT-450/r, ombitasvir with/without dasabuvir in subjects with mild, moderate and severe renal impairment compared to subjects with normal renal function. AASLD 2014, Boston, MA [abstract 238]. Hepatology. 2014;60(suppl):320A.
- Stirnimann G. Ombitasvir (ABT-267), a novel NS5A inhibitor for the treatment of hepatitis C. Expert Opin Pharmacother. 2014;15:2609–2622.
- Gentile I, Buonomo A, Borgia G. Ombitasvir: a potent pan-genotypic inhibitor of NS5A for the treatment of hepatitis C virus infection. Expert Rev Anti Infect Ther. 2014;12:1033–1043.
- Roth D, Nelson D, Bruchfeld A, et al. C-SURFER: Grazoprevir plus elbasvir in treatment-naïve and treatment-experienced patient with HCV genotype 1 infection and chronic kidney disease. EASL, Vienna, Austria [abstract LP02]. J Hepatol. 2015;62(suppl):263–264.
- Caccamo G, Saffioti F, Raimondo G. Hepatitis B virus and hepatitis C virus dual infection. World J Gastroenterol. 2014;20:14559–14567.
- Fernández-Montero JV, Soriano V. Management of hepatitis C in HIV and/or HBV co-infected patients. Best Pract Res Clin Gastroenterol. 2012;26:517–530.
- Zhou J, Dore G, Zhang F, et al. Hepatitis B and C virus coinfection in the TREAT Asia Observational database. J Gastroenterol Hepatol. 2007;22:1510–1518.
- Pontisso P, Ruvoletto M, Fattovich G, et al. Clinical and virological profiles in patients with multiple hepatitis virus infections. Gastroenterology. 1993;105:1529–1533.
- Chu C, Lee S. Hepatitis B virus/hepatitis C virus coinfection: epidemiology, clinical features, viral interactions and treatment. J Gastroenterol Hepatol. 2008;23:512–520.
- Soriano V, Barreiro P, Martin-Carbonero L, et al. Treatment of chronic hepatitis B or C in HIV-infected patients with dual viral hepatitis. J Infect Dis. 2007;195:1181–1183.
- Liu C, Chen P, Lai M, et al. Ribavirin and interferon is effective for hepatitis C virus clearance in hepatitis B and C dually infected patients. Hepatology. 2003;37:568–576.
- Liu C, Chuang W, Lee C, et al. Peginterferon alfa-2b plus ribavirin for the treatment of dual chronic infection with hepatitis B and C viruses. Gastroenterology. 2009;136:496–504.
- Collins J, Raphael K, Terry C, et al. Hepatitis B reactivation during successful treatment of hepatitis C with sofosbuvir and simeprevir. Clin Infect Dis. 2015;61:1304–1306.
This study records for the first time two cases of HBV reactivation during successful DAA therapy for hepatitis C.
- Wahle R, Perez R, Pereira P, et al. Hepatitis B virus reactivation after treatment for hepatitis C in hemodialysis patients with HBV/HCV coinfection. Braz J Infect Dis. 2015;19:533–537.
- Soriano V, Labarga P, De Mendoza C, et al. Emerging challenges in managing hepatitis B in HIV patients. Curr HIV/AIDS Rep. 2015;12:344–352.
- Soriano V, Gallego L. Viral hepatitis: treating hepatitis C in injection drug users. Nat Rev Gastroenterol Hepatol. 2013;10:568–569.
- Robaeys G, Grebely J, Mauss S, et al. Recommendations for the management of hepatitis C virus infection among people who inject drugs. Clin Infect Dis. 2013;57(suppl 2):129–137.
- Hellard M, Sacks-Davis R, Gold J. Hepatitis C treatment for injection drug users: a review of the available evidence. Clin Infect Dis. 2009;49:561–573.
- Paraskevis D, Nikolopoulos G, Fotiou A, et al. Economic recession and emergence of an HIV-1 outbreak among drug injectors in Athens metropolitan area: a longitudinal study. PLoS One. 2013;8(e78941):1.
- Strathdee S, Beyrer C. Threading the needle – how to stop the HIV outbreak in rural Indiana. N Engl J Med. 2015;373:397–399.
- Soriano V, Sherman K, Rockstroh J, et al. Challenges and opportunities for hepatitis C drug development in HIV-HCV coinfected patients. Aids. 2011;25:2197–2208.
- Altice F, Kamarulzaman A, Soriano V, et al. Treatment of medical, psychiatric, and substance use comorbidities in people infected with HIV who use drugs. Lancet. 2010;376:367–387.
- Naggie S, Sulkowski M. Management of patients coinfected with HCV and HIV: a close look at the role for direct-acting antivirals. Gastroenterology. 2012;142:1324–1334.
- Lacombe K, Rockstroh J. HIV and viral hepatitis coinfections: advances and challenges. Gut. 2012;61(suppl 1):47–58.
- Pineda JA, Nuñez-Torres R, Tellez F, et al. HCV reinfection after sustained virological response in HIV-infected patient with chronic hepatitis C. J Infect. 2015 Jul 23. pii: S0163-4453(15)00231-5. DOI:10.1016/j.jinf.2015.07.006. [Epub ahead of print].
- Svarovskaia E, Martin R, Chodavarapu K, et al. HCV reinfection cases in phase 3 studies of sofosbuvir. EASL, Vienna, Austria [abstract O063]. J Hepatol. 2015;62(suppl):222–223.
- Soriano V, Labarga P, De Mendoza C, et al. Acute hepatitis C virus re-infection in a heterosexual HIV-positive partner. Liver Int. 2015 May 2. DOI:10.1111/liv.12858. [Epub ahead of print].
- Martin T, Martin N, Hickman M, et al. Hepatitis C virus reinfection incidence and treatment outcome among HIV-positive MSM. Aids. 2013;27:2551–2557.
- Melin P, Chousterman M, Fontanges T, et al. Effectiveness of chronic hepatitis C treatment in drug users in routine clinical practice: results of a prospective cohort study. Eur J Gastroenterol Hepatol. 2010;22:1050–1057.
- Gallego L, Barreiro P, López-Ibor JJ. Diagnosis and clinical features of major neuropsychiatric disorders in HIV infection. AIDS Rev. 2011;13:171–179.
- Soriano V, Vispo E, Poveda E, et al. Treatment failure with new hepatitis C drugs. Expert Opin Pharmacother. 2012;13:313–323.
- Barreiro P, Labarga P, Fernandez-Montero JV, et al. Rate and predictors of serum HCV-RNA >6 million IU/mL in patients with chronic hepatitis C. J Clin Virol. 2015;71:63–66.
- Krishnan P, Tripathi R, Schnell G, et al. Resistance analysis of baseline and treatment-emergent variants in the AVIATOR study with paritaprevir/r, ombitasvir and dasabuvir in HCV genotype 1. Antimicrob Agents Chemother. 2015;59:5445–5454.
- Hedskog C, Dvory-Sobol H, Gontcharova V, et al. Evolution of the HCV viral population from a patient with S282T detected at relapse after sofosbuvir monotherapy. J Viral Hepat. 2015;22:871–881.
- Yoshimi S, Imamura M, Murakami E, et al. Long term persistence of NS5A inhibitor-resistant hepatitis C virus in patients who failed daclatasvir and asunaprevir therapy. J Med Virol. 2015;87:1913–1920.
- Krishnan P, Tripathi R, Schnell G, et al. Long-term follow-up of treatment-emergent resistance-associated variants in NS3, NS5A and NS5B with paritaprevir/r, ombitasvir and dasabuvir-based regimens. EASL, Vienna, Austria [abstract O057]. J Hepatol. 2015;62(suppl):220.
- Dvory-Sobol H, Wyles D, Ouyang W, et al. Long-term persistence of HCV NS5A variants after treatment with NS5A inhibitor ledipasvir. EASL, Vienna, Austria [abstract O059]. J Hepatol. 2015;62(suppl):221.
- Buti M, Riveiro-Barciela M, Esteban R. Management of direct antiviral agent failures. J Hepatol. 2015 Aug 20. pii: S0168-8278(15)00552-8. DOI:10.1016/j.jhep.2015.08.010. [Epub ahead of print].
- Osinusi A, Kohli A, Marti M, et al. Re-treatment of chronic hepatitis C virus genotype 1 infection after relapse: an open-label pilot study. Ann Intern Med. 2014;161:634–638.
- Lawitz E, Flamm S, Yang J, et al. Re-treatment of patients who failed 8 or 12 weeks of ledipasvir/sofosbuvir-based regimens with ledipasvir/sofosbuvir for 24 weeks. EASL, Vienna, Austria [abstract O005]. J Hepatol. 2015;62(suppl):192.
- Ogawa E, Furusyo N, Dohmen K, et al. Effectiveness of triple therapy with simeprevir for chronic hepatitis C genotype 1b patients with prior telaprevir failure. J Viral Hepat. 2015;22:992–1001.
- Sherman A, Sherman K. Extrahepatic manifestations of hepatitis C infection: navigating CHASM. Curr HIV/AIDS Rep. 2015 Sep;12(3):353–361.
- Soriano V, Labarga P, Fernandez-Montero JV, et al. Hepatitis C cure with antiviral therapy - benefits beyond the liver. Antivir Ther. 2015 Jun 25. DOI:10.3851/IMP2975. [Epub ahead of print].
- Negro F, Forton D, Craxi A, et al. Extrahepatic morbidity and mortality of chronic hepatitis C. Gastroenterology. 2015 Aug 28. pii: S0016-5085(15)01203-2. DOI:10.1053/j.gastro.2015.08.035. [Epub ahead of print].
- Iorio R, Giannattasio A, Sepe A, et al. Chronic hepatitis C in childhood: an 18-year experience. Clin Infect Dis. 2005;41:1431–1437.
- Serranti D, Indolfi G, Resti M. New treatments for chronic hepatitis C: an overview for paediatricians. World J Gastroenterol. 2014;20:15965–15974.
- Beste L, Bondurant H, Ioannou G. Prevalence and management of chronic hepatitis C virus infection in women. Med Clin N Am. 2015;99:575–586.
- Roberts S, Miller R, Jones J, et al. The Ribavirin Pregnancy Registry: Findings after 5 years of enrollment, 2003-2009. Birth Defects Res A Clin Mol Teratol. 2010;88:551–559.
- Vespasiani-Gentilucci U, Galati G, Gallo P, et al. Hepatitis C treatment in the elderly: new possibilities and controversies towards interferon-free regimens. World J Gastroenterol. 2015;21:7412–7426.
- Renet S, Chaumais MC, Antonini T, et al. Extreme bradycardia after first doses of sofosbuvir and daclatasvir in patients receiving amiodarone: 2 cases including a rechallenge. Gastroenterology. 2015 Aug 4. pii: S0016-5085(15)01083-5. DOI:10.1053/j.gastro.2015.07.051. [Epub ahead of print].
- Soriano V, Barreiro P, De Mendoza C. Hypoglycemia in a diabetic patient during hepatitis C therapy. Hepatology. 2015 Aug 27. DOI:10.1002/hep.28137. [Epub ahead of print].
- Bickerstaff C. The cost-effectiveness of novel direct acting antiviral agent therapies for the treatment of chronic hepatitis C. Expert Rev Pharmacoecon Outcomes Res. 2015;15:787–800.
- Everhart J, Lok A, Kim H, et al. Weight-related effects on disease progression in the HALT-C trial. Gastroenterology. 2009;137:549–557.
- Afdhal N, Zeuzem S, Kwo P, et al. Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. N Engl J Med. 2014;370:1889–1898.
- Franco S, Tural C, Nevot M, et al. Detection of a sexually transmitted HCV protease inhibitor-resistance variant in a HIV-infected homosexual man. Gastroenterology. 2014;147:599–601.
- Arends J, Lieveld F, Boeijen L, et al. Natural history and treatment of HCV/HIV coinfection: is it time to change paradigms? J Hepatol. 2015;63:1254–1262.
- Najafzadeh M, Andersson K, Shrank W, et al. Cost-effectiveness of novel regimens for the treatment of hepatitis C virus. Ann Intern Med. 2015;162:407–419.